GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates AS (OCSE:VIRO) » Definitions » EV-to-FCF

ViroGates AS (OCSE:VIRO) EV-to-FCF : -4.25 (As of Apr. 07, 2025)


View and export this data going back to 2018. Start your Free Trial

What is ViroGates AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ViroGates AS's Enterprise Value is kr51.08 Mil. ViroGates AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was kr-12.02 Mil. Therefore, ViroGates AS's EV-to-FCF for today is -4.25.

The historical rank and industry rank for ViroGates AS's EV-to-FCF or its related term are showing as below:

OCSE:VIRO' s EV-to-FCF Range Over the Past 10 Years
Min: -49.54   Med: -7.47   Max: -2.32
Current: -4.25

During the past 8 years, the highest EV-to-FCF of ViroGates AS was -2.32. The lowest was -49.54. And the median was -7.47.

OCSE:VIRO's EV-to-FCF is ranked worse than
100% of 387 companies
in the Medical Devices & Instruments industry
Industry Median: 25.04 vs OCSE:VIRO: -4.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-07), ViroGates AS's stock price is kr6.88. ViroGates AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-2.053. Therefore, ViroGates AS's PE Ratio (TTM) for today is At Loss.


ViroGates AS EV-to-FCF Historical Data

The historical data trend for ViroGates AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates AS EV-to-FCF Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -3.36 -14.06 -20.58 -8.71 -2.30

ViroGates AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.88 -2.30 -2.78 -3.25 -2.91

Competitive Comparison of ViroGates AS's EV-to-FCF

For the Medical Devices subindustry, ViroGates AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates AS's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ViroGates AS's EV-to-FCF falls into.


;
;

ViroGates AS EV-to-FCF Calculation

ViroGates AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=51.082/-12.017
=-4.25

ViroGates AS's current Enterprise Value is kr51.08 Mil.
ViroGates AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-12.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViroGates AS  (OCSE:VIRO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

ViroGates AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.88/-2.053
=At Loss

ViroGates AS's share price for today is kr6.88.
ViroGates AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.053.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ViroGates AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ViroGates AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroGates AS Business Description

Traded in Other Exchanges
N/A
Address
Banevaenget 13, Birkerod, DNK, DK-3460
ViroGates AS is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates AS Headlines

No Headlines